IQV Stock Analysis: IQVIA Holdings | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 32.267m USD | 12M Return: 26.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 292M
EPS Trend: 11.0%
Qual. Beats: 0
Rev. Trend: 97.2%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights, and healthcare intelligence, serving pharmaceutical, biotechnology, medical device, and consumer health companies across the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Technology & Analytics Solutions (cloud-based applications, real-world evidence, and analytics); Research & Development Solutions (clinical trial management, central laboratory, and bioanalytical services); and Contract Sales & Medical Solutions (healthcare provider engagement and medical affairs services). Headquartered in Durham, North Carolina, IQVIA was formerly known as Quintiles IMS Holdings before rebranding in November 2017.
As a major participant in the life sciences tools and services sub-industry, IQVIA operates as a Contract Research Organization (CRO), offering outsourced capabilities that allow drug developers to reduce fixed costs and access specialized expertise across the clinical development lifecycle. The companys combination of clinical research operations with proprietary data assets positions it within the broader real-world evidence and healthcare analytics market, where providers monetize anonymized prescription, sales, and treatment data to inform commercialization strategies for life sciences clients.
IQVIA maintains a strategic collaboration with Kexing Biopharm Co., Ltd. focused on biosimilar development, reflecting the growing role of biologics and biosimilars in the global pharmaceutical pipeline. The firm was incorporated in 2013 and trades on the NYSE under the ticker IQV, with a large-cap market capitalization.
- Clinical trial demand lifts R&D Solutions segment revenue
- Technology and Analytics bookings grow with pharma data spending
- Debt paydown continues as free cash flow supports buybacks
| Net Income: 1.39b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.66 > 1.0 |
| NWC/Revenue: -12.68% < 20% (prev -8.18%; Δ -4.50% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.70b > Net Income 1.39b |
| Net Debt (14.3b) to EBITDA (3.52b): 4.08 < 3 |
| Current Ratio: 0.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (169.8m) vs 12m ago -4.28% < -2% |
| Gross Margin: 26.11% > 18% (prev 32.98%; Δ -6.87% > 0.5%) |
| Asset Turnover: 58.36% > 50% (prev 56.72%; Δ 1.64% > 0%) |
| Interest Coverage Ratio: 3.11 > 6 (EBIT TTM 2.35b / Interest Expense TTM 756.0m) |
| A: -0.07 (Total Current Assets 6.22b - Total Current Liabilities 8.33b) / Total Assets 29.7b |
| B: 0.26 (Retained Earnings 7.70b / Total Assets 29.7b) |
| C: 0.08 (EBIT TTM 2.35b / Avg Total Assets 28.5b) |
| D: 0.27 (Book Value of Equity 6.22b / Total Liabilities 23.3b) |
| Altman-Z'' = 1.21 = BB |
| DSRI: 1.10 (Receivables 3.92b/3.31b, Revenue 16.6b/15.5b) |
| GMI: 1.26 (GM 32.98% / 26.11%) |
| AQI: 1.01 (AQ_t 0.76 / AQ_t-1 0.76) |
| SGI: 1.07 (Revenue 16.6b / 15.5b) |
| TATA: -0.04 (NI 1.39b - CFO 2.70b) / TA 29.7b) |
| Beneish M = -2.65 (Cap -4..+1) = A |
As of July 05, 2026, the stock is trading at USD 207.04 with a total of 1,229,400 shares traded. Over the past week, the price has changed by +11.06%, over one month by +13.73%, over three months by +21.27% and over the past year by +26.06%.
Current recommended Stop Loss: 197.80 (which is 4.5% or 1.2 ATR below the current price).
IQVIA Holdings has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy IQV.
- StrongBuy: 14
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 225.5 | 8.9% |
P/E Trailing = 24.0162
P/E Forward = 14.9477
P/S = 1.9181
P/B = 5.128
P/EG = 0.7703
Revenue TTM = 16.6b USD
EBIT TTM = 2.35b USD
EBITDA TTM = 3.52b USD
Long Term Debt = 14.0b USD (from longTermDebt, last quarter)
Short Term Debt = 1.84b USD (from shortTermDebt, last quarter)
Debt = 16.3b USD (from shortLongTermDebtTotal, last quarter) + Leases 232.0m
Net Debt = 14.3b USD (calculated: Debt 16.3b - CCE 1.95b)
Enterprise Value = 46.6b USD (32.3b + Debt 16.3b - CCE 1.95b)
Interest Coverage Ratio = 3.11 (Ebit TTM 2.35b / Interest Expense TTM 756.0m)
EV/FCF = 18.32x (Enterprise Value 46.6b / FCF TTM 2.54b)
FCF Yield = 5.46% (FCF TTM 2.54b / Enterprise Value 46.6b)
FCF Margin = 15.30% (FCF TTM 2.54b / Revenue TTM 16.6b)
Net Margin = 8.33% (Net Income TTM 1.39b / Revenue TTM 16.6b)
Gross Margin = 26.11% ((Revenue TTM 16.6b - Cost of Revenue TTM 12.3b) / Revenue TTM)
Gross Margin QoQ = 32.64% (prev 6.69%)
Tobins Q-Ratio = 1.57 (Enterprise Value 46.6b / Total Assets 29.7b)
Interest Expense / Debt = 4.64% (Interest Expense 756.0m / Debt 16.3b)
Taxrate = 15.33% (250.0m / 1.63b)
NOPAT = 1.99b (EBIT 2.35b * (1 - 15.33%))
Current Ratio = 0.75 (Total Current Assets 6.22b / Total Current Liabilities 8.33b)
Debt / Equity = 2.62 (Debt 16.3b / totalStockholderEquity, last quarter 6.22b)
Debt / EBITDA = 4.08 (Net Debt 14.3b / EBITDA 3.52b)
Debt / FCF = 5.64 (Net Debt 14.3b / FCF TTM 2.54b)
Total Stockholder Equity = 6.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.86% (Net Income 1.39b / Total Assets 29.7b)
RoE = 22.46% (Net Income TTM 1.39b / Total Stockholder Equity 6.17b)
RoCE = 11.67% (EBIT 2.35b / Capital Employed (Equity 6.17b + L.T.Debt 14.0b))
RoIC = 8.91% (NOPAT 1.99b / Invested Capital 22.4b)
WACC = 7.44% (E(32.3b)/V(48.6b) * Re(9.22%) + D(16.3b)/V(48.6b) * Rd(4.64%) * (1-Tc(0.15)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.01 | Cagr: -3.58%
[DCF] Terminal Value 77.97% ; FCFF base≈2.39b ; Y1≈2.74b ; Y5≈4.04b
[DCF] Fair Price = 277.9 (EV 60.7b - Net Debt 14.3b = Equity 46.4b / Shares 166.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 10.95 | EPS CAGR: 0.64% | SUE: 0.50 | # QB: 0
Revenue Correlation: 97.24 | Revenue CAGR: 4.15% | SUE: 1.50 | # QB: 2
EPS current Quarter (2026-06-30): EPS=3.03 | Chg30d=-0.02% | Revisions=+10% | Analysts=17
EPS next Quarter (2026-09-30): EPS=3.25 | Chg30d=+0.18% | Revisions=+72% | Analysts=17
EPS current Year (2026-12-31): EPS=12.81 | Chg30d=+0.05% | Revisions=+62% | GrowthEPS=+7.5% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=14.20 | Chg30d=+0.05% | Revisions=+46% | GrowthEPS=+10.8% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: +53% (up=58, down=17)